133 related articles for article (PubMed ID: 26623720)
1. Immunohistochemical prediction of lapatinib efficacy in advanced HER2-positive breast cancer patients.
Duchnowska R; Wysocki PJ; Korski K; Czartoryska-Arłukowicz B; Niwińska A; Orlikowska M; Radecka B; Studziński M; Demlova R; Ziółkowska B; Merdalska M; Hajac Ł; Myśliwiec P; Zuziak D; Dębska-Szmich S; Lang I; Foszczyńska-Kłoda M; Karczmarek-Borowska B; Żawrocki A; Kowalczyk A; Biernat W; Jassem J;
Oncotarget; 2016 Jan; 7(1):550-64. PubMed ID: 26623720
[TBL] [Abstract][Full Text] [Related]
2. Pilot trial of paclitaxel-trastuzumab adjuvant therapy for early stage breast cancer: a trial of the ECOG-ACRIN cancer research group (E2198).
Schneider BP; O'Neill A; Shen F; Sledge GW; Thor AD; Kahanic SP; Zander PJ; Davidson NE
Br J Cancer; 2015 Dec; 113(12):1651-7. PubMed ID: 26625004
[TBL] [Abstract][Full Text] [Related]
3. A Phase II Randomized Study of Lapatinib Combined With Capecitabine, Vinorelbine, or Gemcitabine in Patients With HER2-Positive Metastatic Breast Cancer With Progression After a Taxane (Latin American Cooperative Oncology Group 0801 Study).
Gómez HL; Neciosup S; Tosello C; Mano M; Bines J; Ismael G; Santi PX; Pinczowski H; Nerón Y; Fanelli M; Fein L; Sampaio C; Lerzo G; Capó A; Zarba JJ; Blajman C; Varela MS; Martínez-Mesa J; Werutsky G; Barrios CH
Clin Breast Cancer; 2016 Feb; 16(1):38-44. PubMed ID: 26642810
[TBL] [Abstract][Full Text] [Related]
4. BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer.
Karachaliou N; Codony-Servat J; Teixidó C; Pilotto S; Drozdowskyj A; Codony-Servat C; Giménez-Capitán A; Molina-Vila MA; Bertrán-Alamillo J; Gervais R; Massuti B; Morán T; Majem M; Felip E; Carcereny E; García-Campelo R; Viteri S; González-Cao M; Morales-Espinosa D; Verlicchi A; Crisetti E; Chaib I; Santarpia M; Luis Ramírez J; Bosch-Barrera J; Felipe Cardona A; de Marinis F; López-Vivanco G; Miguel Sánchez J; Vergnenegre A; Sánchez Hernández JJ; Sperduti I; Bria E; Rosell R
Sci Rep; 2015 Dec; 5():17499. PubMed ID: 26639561
[TBL] [Abstract][Full Text] [Related]
5. Trastuzumab for HER2+ metastatic breast cancer in clinical practice: Cardiotoxicity and overall survival.
Rossi M; Carioli G; Bonifazi M; Zambelli A; Franchi M; Moja L; Zambon A; Corrao G; La Vecchia C; Zocchetti C; Negri E
Eur J Cancer; 2016 Jan; 52():41-9. PubMed ID: 26630533
[TBL] [Abstract][Full Text] [Related]
6. Overcoming crizotinib resistance in ALK-rearranged NSCLC with the second-generation ALK-inhibitor ceritinib.
Muller IB; De Langen AJ; Honeywell RJ; Giovannetti E; Peters GJ
Expert Rev Anticancer Ther; 2016; 16(2):147-57. PubMed ID: 26654422
[TBL] [Abstract][Full Text] [Related]
7. AKT signaling in ERBB2-amplified breast cancer.
Carmona FJ; Montemurro F; Kannan S; Rossi V; Verma C; Baselga J; Scaltriti M
Pharmacol Ther; 2016 Feb; 158():63-70. PubMed ID: 26645663
[TBL] [Abstract][Full Text] [Related]
8. Current challenges in HER2-positive breast cancer.
Puglisi F; Fontanella C; Amoroso V; Bianchi GV; Bisagni G; Falci C; Fontana A; Generali D; Gianni L; Grassadonia A; Moscetti L; Portarena I; Rossi E; Marchetti P
Crit Rev Oncol Hematol; 2016 Feb; 98():211-21. PubMed ID: 26638862
[TBL] [Abstract][Full Text] [Related]
9. Management of hyperglycemia from epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) targeting T790M-mediated resistance.
Villadolid J; Ersek JL; Fong MK; Sirianno L; Story ES
Transl Lung Cancer Res; 2015 Oct; 4(5):576-83. PubMed ID: 26629426
[TBL] [Abstract][Full Text] [Related]
10. Novel therapies in small cell lung cancer.
Mamdani H; Induru R; Jalal SI
Transl Lung Cancer Res; 2015 Oct; 4(5):533-44. PubMed ID: 26629422
[TBL] [Abstract][Full Text] [Related]
11. Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC--A Randomized Phase III Trial.
Hecht JR; Bang YJ; Qin SK; Chung HC; Xu JM; Park JO; Jeziorski K; Shparyk Y; Hoff PM; Sobrero A; Salman P; Li J; Protsenko SA; Wainberg ZA; Buyse M; Afenjar K; Houé V; Garcia A; Kaneko T; Huang Y; Khan-Wasti S; Santillana S; Press MF; Slamon D
J Clin Oncol; 2016 Feb; 34(5):443-51. PubMed ID: 26628478
[TBL] [Abstract][Full Text] [Related]
12. Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial.
Yardley DA; Brufsky A; Coleman RE; Conte PF; Cortes J; Glück S; Nabholtz JM; O'Shaughnessy J; Beck RM; Ko A; Renschler MF; Barton D; Harbeck N
Trials; 2015 Dec; 16():575. PubMed ID: 26673577
[TBL] [Abstract][Full Text] [Related]
13. Pathological complete response and prognosis after neoadjuvant chemotherapy for HER2-positive breast cancers before and after trastuzumab era: results from a real-life cohort.
Hamy AS; Belin L; Bonsang-Kitzis H; Paquet C; Pierga JY; Lerebours F; Cottu P; Rouzier R; Savignoni A; Lae M; Reyal F
Br J Cancer; 2016 Jan; 114(1):44-52. PubMed ID: 26657653
[TBL] [Abstract][Full Text] [Related]
14. Trastuzumab and bevacizumab combined with docetaxel, oxaliplatin and capecitabine as first-line treatment of advanced HER2-positive gastric cancer: a multicenter phase II study.
Meulendijks D; Beerepoot LV; Boot H; de Groot JW; Los M; Boers JE; Vanhoutvin SA; Polee MB; Beeker A; Portielje JE; de Jong RS; Goey SH; Kuiper M; Sikorska K; Beijnen JH; Tesselaar ME; Schellens JH; Cats A
Invest New Drugs; 2016 Feb; 34(1):119-28. PubMed ID: 26643663
[TBL] [Abstract][Full Text] [Related]
15. Niclosamide inhibits epithelial-mesenchymal transition and tumor growth in lapatinib-resistant human epidermal growth factor receptor 2-positive breast cancer.
Liu J; Chen X; Ward T; Mao Y; Bockhorn J; Liu X; Wang G; Pegram M; Shen K
Int J Biochem Cell Biol; 2016 Feb; 71():12-23. PubMed ID: 26643609
[TBL] [Abstract][Full Text] [Related]
16. PIK3CA(H1047R)- and Her2-initiated mammary tumors escape PI3K dependency by compensatory activation of MEK-ERK signaling.
Cheng H; Liu P; Ohlson C; Xu E; Symonds L; Isabella A; Muller WJ; Lin NU; Krop IE; Roberts TM; Winer EP; Arteaga CL; Zhao JJ
Oncogene; 2016 Jun; 35(23):2961-70. PubMed ID: 26640141
[TBL] [Abstract][Full Text] [Related]
17. Comparison of Gefitinib Versus Chemotherapy in Patients with Non-small Cell Lung Cancer with Exon 19 Deletion.
Watanabe S; Inoue A; Nukiwa T; Kobayashi K
Anticancer Res; 2015 Dec; 35(12):6957-61. PubMed ID: 26637922
[TBL] [Abstract][Full Text] [Related]
18. Fibrocyte-like cells mediate acquired resistance to anti-angiogenic therapy with bevacizumab.
Mitsuhashi A; Goto H; Saijo A; Trung VT; Aono Y; Ogino H; Kuramoto T; Tabata S; Uehara H; Izumi K; Yoshida M; Kobayashi H; Takahashi H; Gotoh M; Kakiuchi S; Hanibuchi M; Yano S; Yokomise H; Sakiyama S; Nishioka Y
Nat Commun; 2015 Dec; 6():8792. PubMed ID: 26635184
[TBL] [Abstract][Full Text] [Related]
19. A phase 1b trial of the combination of an all-oral regimen of capecitabine and erlotinib in advanced non-small cell lung cancer in Caucasian patients.
Kumar R; Lu SK; Minchom A; Sharp A; Davidson M; Gunapala R; Yap TA; Bhosle J; Popat S; O'Brien ME
Cancer Chemother Pharmacol; 2016 Feb; 77(2):375-83. PubMed ID: 26706729
[TBL] [Abstract][Full Text] [Related]
20. Aberrant Splicing of Estrogen Receptor, HER2, and CD44 Genes in Breast Cancer.
Inoue K; Fry EA
Genet Epigenet; 2015; 7():19-32. PubMed ID: 26692764
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
